Hologic, Inc. $HOLX Shares Sold by Panagora Asset Management Inc.

Key Points

• Panagora Asset Management Inc. reduced its stake in Hologic, Inc. by 23.9%, selling 213,876 shares, but still holds 680,642 shares valued at approximately $42 million.
• Other institutional investors, such as Victory Capital Management Inc. and Invesco Ltd., have increased their holdings in Hologic, highlighting strong institutional interest with 94.73% of the stock owned by institutional investors.
• Analysts have set a consensus target price of $78.00 for Hologic shares, with several upgrades indicating increasing confidence in the stock, including a recent upgrade by Citigroup to a "buy" rating.

Panagora Asset Management Inc. cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 23.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 680,642 shares of the medical equipment provider's stock after selling 213,876 shares during the quarter. Panagora Asset Management Inc. owned 0.31% of Hologic worth $42,043,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Beverly Hills Private Wealth LLC boosted its stake in Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after acquiring an additional 180 shares during the last quarter. Allworth Financial LP raised its position in Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the last quarter. Baker Avenue Asset Management LP boosted its position in shares of Hologic by 0.5% during the 4th quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock valued at $3,031,000 after purchasing an additional 225 shares in the last quarter. Integrated Advisors Network LLC lifted its stake in shares of Hologic by 5.4% in the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after buying an additional 289 shares in the last quarter. Finally, Townsquare Capital LLC raised its position in Hologic by 4.5% in the 1st quarter. Townsquare Capital LLC now owns 6,763 shares of the medical equipment provider's stock valued at $418,000 after buying an additional 293 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of analyst reports. Evercore ISI raised their price target on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Saturday. Morgan Stanley increased their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Stephens reduced their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Finally, Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $78.00.

Hologic Stock Performance

NASDAQ:HOLX traded down $0.37 during mid-day trading on Wednesday, reaching $66.24. The stock had a trading volume of 1,411,645 shares, compared to its average volume of 2,718,575. The business has a 50 day simple moving average of $66.24 and a 200 day simple moving average of $62.54. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The firm has a market capitalization of $14.73 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 2.44 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue was up 1.2% on a year-over-year basis. During the same period last year, the company posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.